Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM)

S Christgau, LB Tankó, PAC Cloos, U Mouritzen… - Menopause, 2004 - journals.lww.com
Objective: Several observational studies indicate that estrogen deficiency increases the
incidence of osteoarthritis in postmenopausal women. To validate this observation, we …

Appendicular lean tissue mass and the prevalence of sarcopenia among healthy women

L Movsesyan, U Mouritzen… - Metabolism …, 2002 - metabolismjournal.com
Studies indicate that deficient skeletal muscle mass or sarcopenia is a major cause of
disability and morbidity among the elderly. In part, due to the lack of generally applicable …

Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial

ID Davis, B Brady, RF Kefford, M Millward, J Cebon… - Clinical Cancer …, 2009 - AACR
Abstract Purpose: Human interleukin-21 (IL-21) is a class I cytokine that mediates activation
of CD8+ T cells, natural killer (NK) cells, and other cell types. We report final clinical and …

Pharmacokinetic and pharmacodynamic characteristics of dasiglucagon, a novel soluble and stable glucagon analog

U Hoevelmann, BV Bysted, U Mouritzen… - Diabetes …, 2018 - Am Diabetes Assoc
OBJECTIVE Treatment of severe hypoglycemia outside of the hospital setting is limited to
glucagon formulations requiring reconstitution before use, which may lead to erroneous or …

Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial

RM Naimi, M Hvistendahl, LH Enevoldsen… - The Lancet …, 2019 - thelancet.com
Background Patients with short bowel syndrome might have impaired postprandial
endogenous glucagon-like peptide-2 (GLP-2) secretion, which is required for optimal …

Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial

H Schmidt, J Brown, U Mouritzen, P Selby, K Fode… - Clinical Cancer …, 2010 - AACR
Purpose: This phase I study in patients with metastatic melanoma (MM) and renal cell
carcinoma (RCC) evaluated the safety and maximum tolerated dose (MTD) …

Safety, PK, and PD of recombinant anti-interleukin-21 monoclonal antibody in a first-in-human trial

S Ignatenko, BK Skrumsager… - International journal of …, 2016 - search.proquest.com
Objective: This first-in-human, randomized, double-blind, placebo-controlled trial assessed
the safety of NNC0114-0005, a human recombinant anti interleukin (IL)-21 monoclonal …

[HTML][HTML] Connexin 43: A target for the treatment of inflammation in secondary complications of the kidney and eye in diabetes

CL Cliff, BM Williams, CE Chadjichristos… - International journal of …, 2022 - mdpi.com
Of increasing prevalence, diabetes is characterised by elevated blood glucose and chronic
inflammation that precedes the onset of multiple secondary complications, including those of …

Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus

U Hövelmann, MB Olsen, U Mouritzen… - Diabetes, Obesity …, 2019 - Wiley Online Library
Aim To characterize the pharmacokinetic and pharmacodynamic properties of dasiglucagon,
a novel, stable and liquid formulated glucagon analogue, during hypoglycaemic and …

A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC)

V Grünwald, IME Desar, J Haanen, W Fiedler… - Acta …, 2011 - Taylor & Francis
Background. Sunitinib induces partial responses in 47% of patients with metastatic renal cell
carcinoma (mRCC). However, the achievement of complete responses remains scarce and …